K-679 / Kowa - LARVOL DELTA

Selective intratumoral distribution and post-T-DXd activity of K-679, an ultra-high-DAR EGFR-targeted antibody drug-loaded unimicelle conjugate (ADUC) (AACR 2026) - "We investigated whether the ADUC design of K-679 enables tumor-selective pharmacokinetics (PK), extensive intratumoral distribution, spatial pharmacodynamics, and activity following prior T-DXd treatment. K-679 versus a benchmark ADC (cetuximab‑DM1 ADC, cleavable disulfide linker, DAR ~4.5) was evaluated in head-to-head comparisons using EGFR-expressing CDX (HT-29, SK‑OV-3, SK-CO-1 [KRAS G13V]) evaluated at DM1-equivalent dosing. The ultra-high-DAR ADUC design of K-679 confers tumor-selective PK, extensive intratumoral distribution, concordant spatial pharmacodynamics, and activity after prior T-DXd. These data support clinical development for EGFR-expressing solid tumors with low/heterogeneous antigen density and post-T-DXd settings."

ADC • Oncology • Solid Tumor • CD31 • HER-2 • KRAS • PECAM1

Hepatocyte ApoJ accelerates injury-induced liver fibrosis by activation STAT3 through Ranbp2 mediated-SUMOylation. (PubMed, Cell Mol Gastroenterol Hepatol) - "ApoJ plays a pivotal role in accelerating the progression of liver fibrosis. Therapeutic strategies targeting the ApoJ/STAT3/RanBP2 axis may offer a novel approach for the prevention and treatment of fibrotic liver diseases."

Journal • Fibrosis • Gastroenterology • Hepatology • Immunology • Liver Cirrhosis • Liver Failure • CLU • RANBP2 • STAT3 • TGFB1

K-679: A novel, ultra-high-DAR antibody drug-loaded unimicelle conjugate (ADUC) enabling more effective treatment in EGFR-expressing solid tumors compared to general ADCs (AACR 2025) - "Using this platform, we developed K-679, which combines cetuximab with DM1-loaded unimicelles. Antigen-binding specificity and cellular internalization of K-679 were evaluated using surface plasmon resonance, flow cytometry, and fluorescence microscopy. Our findings establish K-679 as a promising therapeutic candidate for heterogeneous EGFR-expressing solid tumors, characterized by a more potent anti-tumor effect through an exceptionally high DAR, enhanced drug accumulation into tumors and significant bystander effect."

Oncology • Solid Tumor • EGFR

K-679: A Novel Antibody Drug-loaded Unimicelle Conjugate with Ultra-High Drug Loading Capacity Demonstrates Superior Efficacy in EGFR-Expressing Solid Tumors (PRNewswire) - "Kowa Company...today announced an upcoming presentation of non-clinical data for K-679...The compound, developed using Kowa's proprietary micelle technology, has demonstrated superior efficacy in EGFR-expressing solid tumors compared to conventional antibody drug conjugates (ADCs). The data will be presented at The American Association for Cancer Research (AACR) Annual Meeting 2025, taking place April 25th-30th, 2025 in Chicago, Illinois."

Preclinical • Solid Tumor